Basel, 21 April 2021 
 
 
   -- Group sales increase 3%1 at constant exchange rates (CER); 1% decline in 
      Swiss francs, as a result of the appreciation of the Swiss franc 
 
   -- Pharmaceuticals Division sales: 
 
          -- Continued strong growth of new medicines (+20%) 
 
          -- As expected, significant impact from biosimilars (CHF -1.6 
             billion) 
 
          -- Base effect from the strong first quarter 2020 (negative impact of 
             the pandemic only since April 2020) 
 
          -- Overall, this results in a 9% decline in sales. 
 
 
   -- Diagnostics Division sales: 
 
          -- All businesses contribute to very strong growth of 55% 
 
 
   -- Roche's contributions to the fight against the COVID-19 pandemic in the 
      first quarter: 
 
          -- SARS-CoV-2 Rapid Antigen Test Nasal to quickly identify people 
             with the highest risk to be infectious (using simple nasal swabs) 
             receives CE mark and special approvals for self-testing in several 
             countries 
 
          -- Research-use cobas SARS-CoV-2 Variant Set 1 Test launched to help 
             monitor coronavirus mutations 
 
          -- Continued ramp-up of production capacity for COVID-19-related 
             diagnostics and medicines 
 
          -- Partnership with Regeneron: Antibody combination 
             casirivimab/imdevimab is now benefitting patients in an increasing 
             number of countries, incl. the US, Germany, Italy, France and 
             Switzerland Positive results of phase III studies in both COVID-19 
             prevention (reduction of symptomatic infections by 81%) and 
             treatment (reduction of hospitalisation or death by 70%) 
 
   -- Positive phase III results for Tecentriq in early lung cancer and for eye 
      medicine faricimab 
 
   -- Important approvals for medicines in the first quarter: 
 
          -- USA: Actemra/RoActemra for a rare lung disease; Xolair as a 
             pre-filled syringe (eg, allergic asthma) 
 
          -- Europe: Evrysdi for spinal muscular atrophy 
 
   -- Roche signs definitive merger agreement with GenMark Diagnostics 
 
   -- Outlook for 2021 confirmed 
 
   Commenting on the Group's performance in the first quarter, Roche CEO 
Severin Schwan said: 
 
   "In 2021, Roche remains strongly committed to the fight against 
COVID-19. The uptake of our recently introduced diagnostic tests and 
medicines remains strong, while we continue to see the expected impact 
from biosimilars on sales of our established medicines. Our broad 
product pipeline keeps making good progress. I am particularly pleased 
about the highly encouraging study results of our immunotherapy 
Tecentriq in early lung cancer and of faricimab in ophthalmology. The 
upcoming acquisition of GenMark underlines our commitment to help 
control infectious diseases and antibiotic resistance. Based on the 
results of the first quarter of 2021, we confirm the outlook for the 
full year." 
 
 
 
 
   Sales                   CHF millions        As % of sales     % change 
                       --------------------  ------------------  ---------------- 
   January -- March                                                  At        In 
    2021                    2021       2020      2021      2020     CER       CHF 
---------------------  ---------  ---------  --------  --------  ------  -------- 
   Group sales            14,930     15,143     100.0     100.0       3        -1 
 
   Pharmaceuticals 
    Division              10,600     12,262      71.0      81.0      -9       -14 
      United States        5,292      6,616      35.4      43.7     -14       -20 
      Europe               2,175      2,264      14.6      15.0      -6        -4 
      Japan                  852        948       5.7       6.3      -7       -10 
      International*       2,281      2,434      15.3      16.0       0        -6 
 
   Diagnostics 
    Division               4,330      2,881      29.0      19.0      55        50 
---------------------  ---------  ---------  --------  --------  ------  -------- 
*Asia-Pacific, EEMEA (Eastern Europe, Middle 
 East and Africa), Latin America, Canada, 
 others 
 
 
   Outlook confirmed for 2021 
 
   Despite the continued strong impact of biosimilars, sales are expected 
to grow in the low- to mid-single digit range, at constant exchange 
rates. Core earnings per share are targeted to grow broadly in line with 
sales, at constant exchange rates. Roche expects to increase its 
dividend in Swiss francs further. 
 
   Group results 
 
   In the first quarter of the year, Group sales rose 3% (-1% in CHF) to 
CHF 14.9 billion. The appreciation of the Swiss franc against many 
currencies had a negative impact on the results expressed in Swiss 
francs compared to constant exchange rates. 
 
   Sales in the Pharmaceuticals Division decreased 9% to CHF 10.6 billion, 
mainly because of the continued biosimilars competition and the COVID-19 
pandemic. As expected, the first quarter of 2021 was particularly 
challenging due to base effects, as the pandemic only started to have a 
significant business impact at Roche as of April 2020. 
 
   The impact of biosimilars on sales of the established cancer medicines 
MabThera/Rituxan, Avastin and Herceptin remained significant (combined 
sales reduction of CHF 1.6 billion), especially in the US. 
 
   Moreover, the pandemic continued to have a negative impact overall on 
the division's sales, especially for medicines where regular visits to 
hospitals or health practices are needed (ie, for infusions). This was 
partly compensated by additional sales of medicines used to treat 
COVID-19 (Actemra/RoActemra +22%, mostly for treating patients with 
severe COVID-19-associated pneumonia(2) , plus the recently launched 
antibody combination casirivimab/imdevimab). 
 
   The new medicines (launched since 2012(3) ) grew by 20% (or CHF +880 
million) and generated sales of CHF 5.2 billion. Overall, demand 
continued to grow encouragingly, though here too the impact of the lower 
number of doctor's visits was clearly noticeable. 
 
   In the United States, sales decreased by 14%, as a result of the 
continued competition from biosimilars for the above mentioned cancer 
medicines (combined CHF -1.0 billion). This decline was partially 
compensated for by the new products (mainly Evrysdi, Ocrevus, Hemlibra 
and Tecentriq) and Actemra/RoActemra for COVID-19-associated pneumonia. 
 
   In Europe, sales decreased by 6%, as demand for the new products 
(including the antibody combination casirivimab/imdevimab) was only 
partly able to offset the impact of lower sales for the established 
cancer medicines (mainly Avastin) and impacts of the COVID-19 pandemic. 
 
   In Japan, sales decreased by 7%. This decline was mainly driven by the 
osteoporosis medicine Edirol and the competition from biosimilars. This 
was partially offset by sales of cancer immunotherapy Tecentriq. 
 
   In the International region, sales were stable. The impact of 
biosimilars was compensated by new products (Perjeta, Tecentriq and 
Ocrevus) and COVID-19 related Actemra/RoActemra sales. 
 
   The Diagnostics Division reported very strong sales growth of 55% to CHF 
4.3 billion, mainly due to Roche's comprehensive and growing portfolio 
of COVID-19 tests. The Point of Care and Molecular Lab businesses made 
the largest contributions (+281% and +86%, respectively) with COVID-19 
testing. 
 
   Routine diagnostic testing, which was also greatly affected by the 
COVID-19 pandemic during 2020, recorded strong growth. 
 
   Additional product launches in the first quarter, such as a research-use 
PCR test to help monitor SARS-CoV-2 mutations, further strengthened 
Roche's position as the world's leading supplier of COVID-19 tests. 
 
   All regions reported very strong sales growth: EMEA(4) and Asia-Pacific 
(both +62%), North America (+34%) and Latin America (+71%). 
 
   In March, Roche signed a definitive merger agreement with GenMark 
Diagnostics for approx. USD 1.8 billion(5) . Acquiring GenMark will give 
Roche access to a novel technology that can test a wide range of 
pathogens with one patient sample. It will broaden Roche's molecular lab 
portfolio, including tests for COVID-19. The transaction is expected to 
close in the second quarter of 2021. 
 
   COVID-19: Roche's response to the pandemic in the first quarter 2021 
 
   Roche is making a significant effort globally to assist the fight 
against COVID-19. We now have 18 diagnostic solutions that help to 
detect and diagnose the infection and thereby help to prevent the spread 
of the pandemic, and we are providing digital support to healthcare 
systems. Roche also continues to explore the potential of its 
investigational molecules and existing portfolio of medicines. 
 
   In addition, Roche entered into a number of partnerships, including with 
Gilead, Regeneron and Atea, to develop, manufacture and/or distribute 
molecules that potentially can both treat and prevent COVID-19. 
 
   COVID-19: Diagnostics 
 
   Reliable, high-quality testing is essential to help healthcare systems 
overcome this pandemic. In February, Roche obtained the CE mark(6) for 
its new SARS-CoV-2 Rapid Antigen Test Nasal (for professional use). It 
collects the sample from the front area of the nose instead of the 
nasopharynx, resulting in a more comfortable and faster testing 
procedure, with results ready after only 15 minutes. 
 
   Shortly after, the test received special approval in several European 
countries for patient self-testing at home. It can quickly identify 
people with the highest potential to be infectious so they can take 
immediate action. Regular self-testing at home can be one element of 
national testing strategies to reduce pressure on healthcare systems. 
 
   Viruses naturally evolve over time. Roche's research-use solution, the 
cobas SARS-CoV-2 Variant Set 1 Test, provides laboratories with a fast 
and efficient way to investigate these variants found in infected 
individuals. The test is designed to detect key spike mutations in virus

(MORE TO FOLLOW) Dow Jones Newswires

April 21, 2021 01:00 ET (05:00 GMT)